Ambler class A extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. in Canadian hospitals
about
Tracking Change: A Look at the Ecological Footprint of Antibiotics and Antimicrobial ResistanceA Review of SHV Extended-Spectrum β-Lactamases: Neglected Yet UbiquitousMolecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11Molecular characterization of cefoxitin-resistant Escherichia coli from Canadian hospitalsEmergence of and risk factors for ciprofloxacin-gentamicin-resistant Escherichia coli urinary tract infections in a region of Quebec.Antimicrobial resistance gene distribution: a socioeconomic and sociocultural perspectiveThe first report of Escherichia fergusonii isolated from non-human primates, in Africa.Countrywide spread of community- and hospital-acquired extended-spectrum beta-lactamase (CTX-M-15)-producing Enterobacteriaceae in Lebanon.First description of an extended-spectrum-beta-lactamase-producing multidrug-resistant Escherichia fergusonii strain in a patient with cystitis.Development of a multiplex PCR and SHV melting-curve mutation detection system for detection of some SHV and CTX-M beta-lactamases of Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae in TaiwanPrevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008).Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcomeAntimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009.Decreased susceptibility to commonly used antimicrobial agents in bacterial pathogens isolated from urinary tract infections in Rwanda: need for new antimicrobial guidelines.Susceptibility of Klebsiella pneumoniae isolates from intra-abdominal infections and molecular characterization of ertapenem-resistant isolatesMolecular epidemiology of CTX-M-producing Escherichia coli in the Calgary Health Region: emergence of CTX-M-15-producing isolatesRecent Emergence of Escherichia coli with Cephalosporin Resistance Conferred by blaCTX-M on Washington State Dairy FarmsUsing nucleic acid microarrays to perform molecular epidemiology and detect novel β-lactamases: a snapshot of extended-spectrum β-lactamases throughout the world.Community-associated methicillin-resistant Staphylococcus aureus, CanadaDecreased susceptibility to noncarbapenem antimicrobials in extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates in Toronto, CanadaExtended-spectrum beta-lactamase-producing bacteria in a tertiary care hospital in Madrid: epidemiology, risk factors and antimicrobial susceptibility patterns.Antimicrobial resistance - Judicious use is the keyDetection of Extended Spectrum B-Lactamases in Urinary Isolates of Klebsiella pneumoniae in Relation to Bla, Bla and Bla Gene Carriage.Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units.Molecular survey of beta-lactamases conferring resistance to newer beta-lactams in Enterobacteriaceae isolates from Polish hospitals.ESBL genotypes in fluoroquinolone-resistant and fluoroquinolone-susceptible ESBL-producing Escherichia coli urinary isolates in ManitobaCharacterization of methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci and extended-spectrum beta-lactamase-producing Escherichia coli in intensive care units in Canada: Results of the Canadian National Intensive Care UnitClinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults.Extended-spectrum beta-lactamase-producing bacteria isolated from hematologic patients in Manaus, State of Amazonas, BrazilCharacterization of cefoxitin-resistant Escherichia coli isolates from recreational beaches and private drinking water in Canada between 2004 and 2006In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance studyMultiresistant Enterobacteriaceae: new threat of an old problem.Risk factors for and outcomes associated with clinical isolates of Escherichia coli and Klebsiella species resistant to extended-spectrum cephalosporins among patients admitted to Canadian hospitals.Complete nucleotide sequence of a 92-kilobase plasmid harboring the CTX-M-15 extended-spectrum beta-lactamase involved in an outbreak in long-term-care facilities in Toronto, Canada.Molecular and kinetic comparison of the novel extended-spectrum beta-lactamases CTX-M-25 and CTX-M-26.Phenotypic and molecular detection of CTX-M-beta-lactamases produced by Escherichia coli and Klebsiella sppNatural evolution of TEM-1 β-lactamase: experimental reconstruction and clinical relevance.Molecular analysis of the simultaneous production of two SHV-type extended-spectrum beta-lactamases in a clinical isolate of Enterobacter cloacae by using single-nucleotide polymorphism genotyping.CTX-M-2 and a new CTX-M-39 enzyme are the major extended-spectrum beta-lactamases in multiple Escherichia coli clones isolated in Tel Aviv, Israel.
P2860
Q27007076-242228A3-6BF8-46FF-81EE-7B3080EFB417Q28076260-DB762523-2069-445D-A92F-D1639D2B599CQ28288964-2A198117-6A65-4907-90CE-68BE35EEB671Q33554703-D48EBB8D-502E-43AB-A2AD-351123A6B423Q33593668-EE1CBF9B-4D63-4D77-8EEB-46E196C5A2C3Q33699757-77EC037A-0024-4DBF-B20D-9470FE63F811Q33753466-6B7FA1EC-0DC2-4C62-AA20-19539942927FQ33884893-3AD716C8-932B-43A2-83F1-B9083F9F60F6Q33909472-B5C215FC-310D-4BAD-BE9C-F9CC68E6A7B3Q34042495-279BA038-5C44-40D9-9B67-C66C68781FD1Q34290139-27755BED-CA4C-4026-B74E-BADFD39F430EQ34351978-AD1FD6A0-46EA-4EDB-9B50-8C32AAEC66E9Q34752032-75019E74-EFCA-47BB-9C03-72F8EE5278A1Q35004919-2CED9551-190F-4804-823D-C04229FEEAF3Q35031841-C8811B75-A7B0-47D7-B267-CE3479463977Q35139440-11B7EE89-F6D1-474B-960F-8F213C13F7AFQ35758933-BE87503C-EAE9-42B8-AC84-7615766EA0F8Q35764110-B3839243-F12A-4D14-9C89-E54061CBC74AQ35942940-FC111BA3-958B-4E61-9992-9912509DCD7CQ36009323-6BD74F3A-50FF-4A63-855B-DB69C52E5B01Q36086414-8E8BA016-6017-480A-BC05-C60006C777DCQ36105222-A41CD16A-BD2D-48FE-B911-F4587E7B6A14Q36170892-35C55BCD-CB35-46A7-8F7C-E6834DD818C4Q36348949-28E573D2-B62E-4D3D-9622-5680149BC9E1Q36593857-F1E3F59F-D30C-4F0B-BE8C-0386E3B9EA25Q36744818-3827866A-60F4-478B-AB50-730DD5C86DF7Q36871054-4F5C7164-C080-4F37-9464-C4D0E39005F2Q37021378-F103C6E9-12A8-4035-901B-3C8114A4B861Q37029217-570F80C1-60AB-4B9E-8650-1C9CEF7F8757Q37159830-06586EA5-DABD-4C49-A913-FDA7F0725393Q37247668-B3B6974A-B802-4D50-85D7-A427E47F615AQ37263425-7D627CA0-A80B-496E-8E8F-2CFD1A13D055Q37291349-E2B06CED-4B7A-4221-ABDD-97766BA933BDQ37405325-58B9A55B-61AC-48CC-B0F9-B1119040496AQ37568365-6B1230E4-551D-4F15-AB3A-89A41E70EE86Q37624427-2B98FE40-446F-4A2C-A902-0621C4040E89Q37702466-8294FEA8-CE48-4331-87FC-5270C4872359Q37735903-B923B2C4-25DA-47E8-A389-93E3FE9030D7Q39609368-F124028F-2A01-43A0-8F0A-1FFD1F02E916Q39609493-4553CF3B-6663-4355-8E34-DBCF1C609BC3
P2860
Ambler class A extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. in Canadian hospitals
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2004
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Ambler class A extended-spectr ...... lla spp. in Canadian hospitals
@en
Ambler class A extended-spectr ...... la spp. in Canadian hospitals.
@nl
type
label
Ambler class A extended-spectr ...... lla spp. in Canadian hospitals
@en
Ambler class A extended-spectr ...... la spp. in Canadian hospitals.
@nl
prefLabel
Ambler class A extended-spectr ...... lla spp. in Canadian hospitals
@en
Ambler class A extended-spectr ...... la spp. in Canadian hospitals.
@nl
P2093
P2860
P1476
Ambler class A extended-spectr ...... lla spp. in Canadian hospitals
@en
P2093
Andrew E Simor
Canadian Hospital Epidemiology ...... illance Program, Health Canada
David Boyd
Elizabeth Bryce
Marianna Ofner-Agostini
Michael R Mulvey
Sara Christianson
Shirley Paton
P2860
P304
P356
10.1128/AAC.48.4.1204-1214.2004
P407
P577
2004-04-01T00:00:00Z